CA2828657C - Utilisation d'il-2 a faible dose pour le traitement de troubles de type auto-immuns ou de troubles inflammatoires - Google Patents

Utilisation d'il-2 a faible dose pour le traitement de troubles de type auto-immuns ou de troubles inflammatoires

Info

Publication number
CA2828657C
CA2828657C CA2828657A CA2828657A CA2828657C CA 2828657 C CA2828657 C CA 2828657C CA 2828657 A CA2828657 A CA 2828657A CA 2828657 A CA2828657 A CA 2828657A CA 2828657 C CA2828657 C CA 2828657C
Authority
CA
Canada
Prior art keywords
interleukin
autoimmune
immune
treating
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2828657A
Other languages
English (en)
Other versions
CA2828657A1 (fr
Inventor
David Klatzmann
David Saadoun
Patrice Cacoub
Michele Rosenzwajg
Eliane Piaggio
Gilbert Bensimon
Claude Bernard
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Sorbonne Universite
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Sorbonne Universite filed Critical Assistance Publique Hopitaux de Paris APHP
Priority claimed from PCT/EP2012/054174 external-priority patent/WO2012123381A1/fr
Publication of CA2828657A1 publication Critical patent/CA2828657A1/fr
Application granted granted Critical
Publication of CA2828657C publication Critical patent/CA2828657C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne de nouvelles thérapies pour le traitement de maladies auto-immunes et inflammatoires. Plus particulièrement, la présente invention concerne l'utilisation d'interleukine-2 à faible dose pour le traitement du diabète de type I ou d'autres maladies auto-immunes et/ou inflammatoires.
CA2828657A 2011-03-11 2012-03-09 Utilisation d'il-2 a faible dose pour le traitement de troubles de type auto-immuns ou de troubles inflammatoires Active CA2828657C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161451663P 2011-03-11 2011-03-11
EP11305269.0 2011-03-11
US61/451,663 2011-03-11
EP11305269 2011-03-11
PCT/EP2012/054174 WO2012123381A1 (fr) 2011-03-11 2012-03-09 Utilisation d'il-2 à faible dose pour le traitement de troubles de type auto-immuns ou de troubles inflammatoires

Publications (2)

Publication Number Publication Date
CA2828657A1 CA2828657A1 (fr) 2012-09-20
CA2828657C true CA2828657C (fr) 2025-11-18

Family

ID=

Similar Documents

Publication Publication Date Title
US12491232B2 (en) Low dose IL-2 for treating autoimmune-related or inflammatory disorders
US11559566B2 (en) Use of low dose IL-2 for treating autoimmune-related or inflammatory disorders
Martin Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis
US12024558B2 (en) Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART
HK40003184B (en) Il-2 dosage regimen for treating systemic lupus erythematosus
HK40003184A (en) Il-2 dosage regimen for treating systemic lupus erythematosus
US20240358790A1 (en) Compositions and methods for treating autoimmunity, including autoimmunity associated with cancer and cancer therapy
IL108318A (en) Method of stimulating peripheral blood mononuclear cell cytolytic ativity by incubating mononuclear cells with il-10
Feinstein et al. Pulmonary infection induced by drugs
Peters The immunological activity of CD4+ CD28null T cells in the pathogenesis of multiple sclerosis